These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 23170181)

  • 1. Neutralization interfering antibodies: a "novel" example of humoral immune dysfunction facilitating viral escape?
    Nicasio M; Sautto G; Clementi N; Diotti RA; Criscuolo E; Castelli M; Solforosi L; Clementi M; Burioni R
    Viruses; 2012 Sep; 4(9):1731-52. PubMed ID: 23170181
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A focus on humoral immunity to viral infections.
    Woodland DL
    Viral Immunol; 2012 Dec; 25(6):441. PubMed ID: 23216306
    [No Abstract]   [Full Text] [Related]  

  • 3. Early low-titer neutralizing antibodies impede HIV-1 replication and select for virus escape.
    Bar KJ; Tsao CY; Iyer SS; Decker JM; Yang Y; Bonsignori M; Chen X; Hwang KK; Montefiori DC; Liao HX; Hraber P; Fischer W; Li H; Wang S; Sterrett S; Keele BF; Ganusov VV; Perelson AS; Korber BT; Georgiev I; McLellan JS; Pavlicek JW; Gao F; Haynes BF; Hahn BH; Kwong PD; Shaw GM
    PLoS Pathog; 2012; 8(5):e1002721. PubMed ID: 22693447
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protective antiviral antibodies that lack neutralizing activity: precedents and evolution of concepts.
    Schmaljohn AL
    Curr HIV Res; 2013 Jul; 11(5):345-53. PubMed ID: 24191933
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glycoprotein N of human cytomegalovirus protects the virus from neutralizing antibodies.
    Kropff B; Burkhardt C; Schott J; Nentwich J; Fisch T; Britt W; Mach M
    PLoS Pathog; 2012; 8(10):e1002999. PubMed ID: 23133379
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sequential evolution and escape from neutralization of simian immunodeficiency virus SIVsmE660 clones in rhesus macaques.
    Wu F; Ourmanov I; Kuwata T; Goeken R; Brown CR; Buckler-White A; Iyengar R; Plishka R; Aoki ST; Hirsch VM
    J Virol; 2012 Aug; 86(16):8835-47. PubMed ID: 22696650
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chikungunya virus neutralization antigens and direct cell-to-cell transmission are revealed by human antibody-escape mutants.
    Lee CY; Kam YW; Fric J; Malleret B; Koh EG; Prakash C; Huang W; Lee WW; Lin C; Lin RT; Renia L; Wang CI; Ng LF; Warter L
    PLoS Pathog; 2011 Dec; 7(12):e1002390. PubMed ID: 22144891
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Two Escape Mechanisms of Influenza A Virus to a Broadly Neutralizing Stalk-Binding Antibody.
    Chai N; Swem LR; Reichelt M; Chen-Harris H; Luis E; Park S; Fouts A; Lupardus P; Wu TD; Li O; McBride J; Lawrence M; Xu M; Tan MW
    PLoS Pathog; 2016 Jun; 12(6):e1005702. PubMed ID: 27351973
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human Monoclonal Antibody Derived from Transchromosomic Cattle Neutralizes Multiple H1 Clades of Influenza A Virus by Recognizing a Novel Conformational Epitope in the Hemagglutinin Head Domain.
    Gao R; Sreenivasan CC; Sheng Z; Hause BM; Zhou B; Wentworth DE; Clement T; Rausch D; Brunick C; Christopher-Hennings J; Wu H; Bausch CL; Sullivan EJ; Hoppe AD; Huber VC; Wang D; Li F
    J Virol; 2020 Oct; 94(22):. PubMed ID: 32847862
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dissection of Epitope-Specific Mechanisms of Neutralization of Influenza Virus by Intact IgG and Fab Fragments.
    Williams JA; Gui L; Hom N; Mileant A; Lee KK
    J Virol; 2018 Mar; 92(6):. PubMed ID: 29263254
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monoclonal antibodies for prophylactic and therapeutic use against viral infections.
    Both L; Banyard AC; van Dolleweerd C; Wright E; Ma JK; Fooks AR
    Vaccine; 2013 Mar; 31(12):1553-9. PubMed ID: 23370150
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cooperation between Strain-Specific and Broadly Neutralizing Responses Limited Viral Escape and Prolonged the Exposure of the Broadly Neutralizing Epitope.
    Anthony C; York T; Bekker V; Matten D; Selhorst P; Ferreria RC; Garrett NJ; Karim SSA; Morris L; Wood NT; Moore PL; Williamson C
    J Virol; 2017 Sep; 91(18):. PubMed ID: 28679760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biphasic CD8+ T-Cell Defense in Simian Immunodeficiency Virus Control by Acute-Phase Passive Neutralizing Antibody Immunization.
    Iseda S; Takahashi N; Poplimont H; Nomura T; Seki S; Nakane T; Nakamura M; Shi S; Ishii H; Furukawa S; Harada S; Naruse TK; Kimura A; Matano T; Yamamoto H
    J Virol; 2016 Jul; 90(14):6276-6290. PubMed ID: 27122584
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glycan Reactive Natural Antibodies and Viral Immunity.
    New JS; King RG; Kearney JF
    Viral Immunol; 2020 May; 33(4):266-276. PubMed ID: 31851873
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conformational Epitope-Specific Broadly Neutralizing Plasma Antibodies Obtained from an HIV-1 Clade C-Infected Elite Neutralizer Mediate Autologous Virus Escape through Mutations in the V1 Loop.
    Patil S; Kumar R; Deshpande S; Samal S; Shrivastava T; Boliar S; Bansal M; Chaudhary NK; Srikrishnan AK; Murugavel KG; Solomon S; Simek M; Koff WC; Goyal R; Chakrabarti BK; Bhattacharya J
    J Virol; 2016 Jan; 90(7):3446-57. PubMed ID: 26763999
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complete mapping of viral escape from neutralizing antibodies.
    Doud MB; Hensley SE; Bloom JD
    PLoS Pathog; 2017 Mar; 13(3):e1006271. PubMed ID: 28288189
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Applying antibody-sensitive hypervariable region 1-deleted hepatitis C virus to the study of escape pathways of neutralizing human monoclonal antibody AR5A.
    Velázquez-Moctezuma R; Law M; Bukh J; Prentoe J
    PLoS Pathog; 2017 Feb; 13(2):e1006214. PubMed ID: 28231271
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Rare Mutation in an Infant-Derived HIV-1 Envelope Glycoprotein Alters Interprotomer Stability and Susceptibility to Broadly Neutralizing Antibodies Targeting the Trimer Apex.
    Mishra N; Sharma S; Dobhal A; Kumar S; Chawla H; Singh R; Das BK; Kabra SK; Lodha R; Luthra K
    J Virol; 2020 Sep; 94(19):. PubMed ID: 32669335
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatitis C Virus Escape Studies of Human Antibody AR3A Reveal a High Barrier to Resistance and Novel Insights on Viral Antibody Evasion Mechanisms.
    Velázquez-Moctezuma R; Galli A; Law M; Bukh J; Prentoe J
    J Virol; 2019 Feb; 93(4):. PubMed ID: 30487284
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of rapid evolutionary escape from biomedical interventions targeting SARS-CoV-2 spike protein.
    Van Egeren D; Novokhodko A; Stoddard M; Tran U; Zetter B; Rogers M; Pentelute BL; Carlson JM; Hixon M; Joseph-McCarthy D; Chakravarty A
    PLoS One; 2021; 16(4):e0250780. PubMed ID: 33909660
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.